Drug Pricing
Commentary
How to give patients a right to save on health care
Shopping around has never been easier. With a few clicks, consumers can easily find deals on flights, get multiple quotes on car insurance or price-match items in their local shopping mall. Yet when it comes to spending money on something really important — their health — consumers are largely in ...
Drug Pricing
NEW BRIEF: Empowering Providers to Promote Healthcare Innovation
These reforms include: Implementing the insurance reforms discussed in Part 5 that, from a provider perspective, will incentivize the creation of innovative payment models. New payment models create opportunities to better align the incentives of providers and patients. Implementing regulatory reforms that include eliminating certificate of need laws, scope ...
Commentary
Price Controls, Publicly Funded Insurance Won’t Deliver Value
On Dec. 14, the Centers for Medicare and Medicaid Services (cms.gov) released their latest estimate of the country’s annual healthcare tab. For the second straight year, U.S. healthcare spending topped $4 trillion. In 2021, health spending accounted for more than 18% of U.S. GDP. Progressives tend to cite numbers like these ...
Commentary
An Effective Treatment for Alzheimer’s, But Only if ICER Allows It
Three days before Christmas, the Institute for Clinical & Economic Review (ICER) is scheduled to publish a draft assessment of two promising treatments for Alzheimer’s disease. Unfortunately for the millions of Americans living with this fatal illness, it is likely that ICER will be giving lumps of coal, not gifts, ...
Drug Prices
NEW STUDY: 340B Providers Reap Big Profits, Should Be Reformed to Ensure At-Risk Patients Receive Affordable Care
SACRAMENTO – The broken 340B program, designed to provide affordable care for at-risk patients, creates massive profits for providers without necessarily improving patient health outcomes and should be reformed, finds a new issue brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute. ...
Commentary
What Is the Value of the Interchangeability Designation for a Biosimilar?
By Wayne Winegarden, Robert Popovian & Peter Pitts Biosimilars, to date, have achieved the promise of reducing prices and drug spending in the United States. The unquestioned safety and efficacy of biosimilars have given providers, patients, and employers, amongst many others, the confidence that savings will be even more robust as we ...
Blog
Health Care Priorities for Next Congress
Election day approaches quickly. But no matter who wins come November, Americans must urge Congress to prioritize health care policy. Health care costs are consistently rising which endangers lives because costs can constrain patients from receiving needed care. Pandemic exigencies further highlighted shortcomings in our health care system. Before pandemic ...
Commentary
Inflation Reduction Act is bad news for patients
Democrats are riding high on the public support they’ve garnered for passing legislation giving Medicare the power to negotiate for lower prices from drug makers. A Politico-Morning Consult Poll found that 76% of Americans support price caps on drugs, while only 13% do not. In other words, Democrats have effectively ...
Drug Prices
Sally Pipes Discusses Prescription Drugs and Inflation Reduction Act on Eric Bolling: The Balance
Watch PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy discuss prescription drug costs and the so-called Inflation Reduction Act on “Eric Bolling: The Balance” on Newsmax TV.
Commentary
Government Drug Price Negotiations Offer A False Promise
With inflation rising and midterm elections just months away, Democrats are desperate for something they can pitch to voters as a reason to keep them in control of Congress. They’re hoping a watered-down version of their Build Back Better Act could do the trick. Sen. Joe Manchin, D-W. Va., who helped shoot the bill ...
How to give patients a right to save on health care
Shopping around has never been easier. With a few clicks, consumers can easily find deals on flights, get multiple quotes on car insurance or price-match items in their local shopping mall. Yet when it comes to spending money on something really important — their health — consumers are largely in ...
NEW BRIEF: Empowering Providers to Promote Healthcare Innovation
These reforms include: Implementing the insurance reforms discussed in Part 5 that, from a provider perspective, will incentivize the creation of innovative payment models. New payment models create opportunities to better align the incentives of providers and patients. Implementing regulatory reforms that include eliminating certificate of need laws, scope ...
Price Controls, Publicly Funded Insurance Won’t Deliver Value
On Dec. 14, the Centers for Medicare and Medicaid Services (cms.gov) released their latest estimate of the country’s annual healthcare tab. For the second straight year, U.S. healthcare spending topped $4 trillion. In 2021, health spending accounted for more than 18% of U.S. GDP. Progressives tend to cite numbers like these ...
An Effective Treatment for Alzheimer’s, But Only if ICER Allows It
Three days before Christmas, the Institute for Clinical & Economic Review (ICER) is scheduled to publish a draft assessment of two promising treatments for Alzheimer’s disease. Unfortunately for the millions of Americans living with this fatal illness, it is likely that ICER will be giving lumps of coal, not gifts, ...
NEW STUDY: 340B Providers Reap Big Profits, Should Be Reformed to Ensure At-Risk Patients Receive Affordable Care
SACRAMENTO – The broken 340B program, designed to provide affordable care for at-risk patients, creates massive profits for providers without necessarily improving patient health outcomes and should be reformed, finds a new issue brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute. ...
What Is the Value of the Interchangeability Designation for a Biosimilar?
By Wayne Winegarden, Robert Popovian & Peter Pitts Biosimilars, to date, have achieved the promise of reducing prices and drug spending in the United States. The unquestioned safety and efficacy of biosimilars have given providers, patients, and employers, amongst many others, the confidence that savings will be even more robust as we ...
Health Care Priorities for Next Congress
Election day approaches quickly. But no matter who wins come November, Americans must urge Congress to prioritize health care policy. Health care costs are consistently rising which endangers lives because costs can constrain patients from receiving needed care. Pandemic exigencies further highlighted shortcomings in our health care system. Before pandemic ...
Inflation Reduction Act is bad news for patients
Democrats are riding high on the public support they’ve garnered for passing legislation giving Medicare the power to negotiate for lower prices from drug makers. A Politico-Morning Consult Poll found that 76% of Americans support price caps on drugs, while only 13% do not. In other words, Democrats have effectively ...
Sally Pipes Discusses Prescription Drugs and Inflation Reduction Act on Eric Bolling: The Balance
Watch PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy discuss prescription drug costs and the so-called Inflation Reduction Act on “Eric Bolling: The Balance” on Newsmax TV.
Government Drug Price Negotiations Offer A False Promise
With inflation rising and midterm elections just months away, Democrats are desperate for something they can pitch to voters as a reason to keep them in control of Congress. They’re hoping a watered-down version of their Build Back Better Act could do the trick. Sen. Joe Manchin, D-W. Va., who helped shoot the bill ...
